FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1997941107> ?p ?o ?g. }

• W1997941107 endingPage "111" @default.
• W1997941107 startingPage "103" @default.
• W1997941107 abstract "Serum prostate specific antigen (PSA) is widely used as a guide to initiate prostatic biopsies and to follow men older than 50 years old with and without prostate cancer. However, benign prostatic hyperplasia (BPH) is a common cause of serum PSA values between 2 and 10 ng./ml. A better understanding of the relationships among serum PSA, prostate cancer and BPH is important.A total of 875 men underwent radical prostatectomy at our institution between December 1984 and January 1997. Of these men 784 had a serum PSA of 2 to 22 ng./ml., including 579 with the largest cancer located in the peripheral zone of the prostate. Of the 579 men 406 had serum PSA followups for greater than 3 years after radical prostatectomy. We examined Pearson correlations (R2) between preoperative serum PSA, and the volume of Gleason grades 4/5 and 3 to 1 cancer in 784 men, separating peripheral zone from transition zone cancers. We used broken line regression with break points of 7 and 9 ng./ml. preoperative PSA to summarize the relationship of each PSA doubling to 5 different morphological variables in 579 men with peripheral zone cancer. A 9 ng./ml. break point was used for prostate weight. Trend summaries with a local regression line for the relationships between 6 morphological variables and PSA were superimposed on full scatterplots of the 579 men with PSA less than 22 ng./ml. Cox proportional hazard models were used to examine 5-year PSA failure-free probabilities based on 406 men with minimal PSA followups greater than 3 years at break points of 7 to 9 ng./ml. PSA.Pearson correlation between cancer volume and preoperative serum PSA in 875 men was weak (r2 = 0.27) and driven by large cancers with serum PSA greater than 22 ng./ml. For peripheral zone cancer the overall R2 x 100 for 641 men with low and high grade cancer was 10% and only 3% for low grade cancer, that is almost no PSA produced by these peripheral zone cancers enters the serum. All morphological variables changed at rates of doubtful medical significance below a PSA of 7 to 9 ng./ml. but at rates that were significantly worse above 9 ng./ml. R2 for these relationships was never greater than 15%. Large individual morphological variations at all levels of PSA emphasize the serious limitation of PSA as a predictor of prostate cancer morphology. Below 9 ng./ml. prostate weight increased by 21% for each doubling of PSA but above 9 ng./ml. the increase was only 4.8%.Preoperative serum PSA has a clinically useless relationship with cancer volume and grade in radical prostatectomy specimens, and a limited relationship with PSA cure rates at preoperative serum PSA levels of 2 to 9 ng./ml. Trend summaries for prostate weight on broken line regression showed that below 9 ng./ml. BPH is a strong contender for the cause of PSA elevation, constituting the primary cause of the over diagnosis of prostate cancer." @default.
• W1997941107 created "2016-06-24" @default.
• W1997941107 creator A5035337773 @default.
• W1997941107 creator A5040267184 @default.
• W1997941107 creator A5068820671 @default.
• W1997941107 creator A5071647275 @default.
• W1997941107 creator A5075982334 @default.
• W1997941107 date "2002-01-01" @default.
• W1997941107 modified "2023-10-16" @default.
• W1997941107 title "PREOPERATIVE SERUM PROSTATE SPECIFIC ANTIGEN LEVELS BETWEEN 2 AND 22 NG./ML. CORRELATE POORLY WITH POST-RADICAL PROSTATECTOMY CANCER MORPHOLOGY: PROSTATE SPECIFIC ANTIGEN CURE RATES APPEAR CONSTANT BETWEEN 2 AND 9 NG./ML." @default.
• W1997941107 cites W11097077 @default.
• W1997941107 cites W116956788 @default.
• W1997941107 cites W147570767 @default.
• W1997941107 cites W1966408394 @default.
• W1997941107 cites W1968629884 @default.
• W1997941107 cites W1969399807 @default.
• W1997941107 cites W1971904043 @default.
• W1997941107 cites W1987763844 @default.
• W1997941107 cites W1988010344 @default.
• W1997941107 cites W1989975266 @default.
• W1997941107 cites W1999380260 @default.
• W1997941107 cites W2010616721 @default.
• W1997941107 cites W2017359766 @default.
• W1997941107 cites W2018722737 @default.
• W1997941107 cites W2034001008 @default.
• W1997941107 cites W2046420293 @default.
• W1997941107 cites W2049153532 @default.
• W1997941107 cites W2051497916 @default.
• W1997941107 cites W2054921086 @default.
• W1997941107 cites W2061879006 @default.
• W1997941107 cites W2076409735 @default.
• W1997941107 cites W2078176021 @default.
• W1997941107 cites W2082709973 @default.
• W1997941107 cites W2094105063 @default.
• W1997941107 cites W2103947475 @default.
• W1997941107 cites W2105548709 @default.
• W1997941107 cites W2122800574 @default.
• W1997941107 cites W2132985516 @default.
• W1997941107 cites W2144629663 @default.
• W1997941107 cites W2145039834 @default.
• W1997941107 cites W2330292521 @default.
• W1997941107 cites W2407415728 @default.
• W1997941107 cites W4233876345 @default.
• W1997941107 cites W4233902993 @default.
• W1997941107 cites W4241208044 @default.
• W1997941107 cites W53877061 @default.
• W1997941107 doi "https://doi.org/10.1016/s0022-5347(05)65392-x" @default.
• W1997941107 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11743285" @default.
• W1997941107 hasPublicationYear "2002" @default.
• W1997941107 type Work @default.
• W1997941107 sameAs 1997941107 @default.
• W1997941107 citedByCount "156" @default.
• W1997941107 countsByYear W19979411072012 @default.
• W1997941107 countsByYear W19979411072013 @default.
• W1997941107 countsByYear W19979411072014 @default.
• W1997941107 countsByYear W19979411072015 @default.
• W1997941107 countsByYear W19979411072016 @default.
• W1997941107 countsByYear W19979411072017 @default.
• W1997941107 countsByYear W19979411072018 @default.
• W1997941107 countsByYear W19979411072019 @default.
• W1997941107 countsByYear W19979411072020 @default.
• W1997941107 countsByYear W19979411072021 @default.
• W1997941107 countsByYear W19979411072022 @default.
• W1997941107 crossrefType "journal-article" @default.
• W1997941107 hasAuthorship W1997941107A5035337773 @default.
• W1997941107 hasAuthorship W1997941107A5040267184 @default.
• W1997941107 hasAuthorship W1997941107A5068820671 @default.
• W1997941107 hasAuthorship W1997941107A5071647275 @default.
• W1997941107 hasAuthorship W1997941107A5075982334 @default.
• W1997941107 hasConcept C121608353 @default.
• W1997941107 hasConcept C126322002 @default.
• W1997941107 hasConcept C126894567 @default.
• W1997941107 hasConcept C147483822 @default.
• W1997941107 hasConcept C203014093 @default.
• W1997941107 hasConcept C2776235491 @default.
• W1997941107 hasConcept C2777562237 @default.
• W1997941107 hasConcept C2779466945 @default.
• W1997941107 hasConcept C2780192828 @default.
• W1997941107 hasConcept C2781406297 @default.
• W1997941107 hasConcept C29456083 @default.
• W1997941107 hasConcept C50382708 @default.
• W1997941107 hasConcept C71924100 @default.
• W1997941107 hasConceptScore W1997941107C121608353 @default.
• W1997941107 hasConceptScore W1997941107C126322002 @default.
• W1997941107 hasConceptScore W1997941107C126894567 @default.
• W1997941107 hasConceptScore W1997941107C147483822 @default.
• W1997941107 hasConceptScore W1997941107C203014093 @default.
• W1997941107 hasConceptScore W1997941107C2776235491 @default.
• W1997941107 hasConceptScore W1997941107C2777562237 @default.
• W1997941107 hasConceptScore W1997941107C2779466945 @default.
• W1997941107 hasConceptScore W1997941107C2780192828 @default.
• W1997941107 hasConceptScore W1997941107C2781406297 @default.
• W1997941107 hasConceptScore W1997941107C29456083 @default.
• W1997941107 hasConceptScore W1997941107C50382708 @default.
• W1997941107 hasConceptScore W1997941107C71924100 @default.
• W1997941107 hasIssue "1" @default.
• W1997941107 hasLocation W19979411071 @default.
• W1997941107 hasLocation W19979411072 @default.

• next